复旦复华涨5% 生物医药政策调整

智选洞察12-25 09:30

12月25日，复旦复华（600624）股价大幅上涨，截至09点30分，复旦复华上涨5.14%，报7.78元/股，成交863万元，换手率0.16%，振幅0.14%。消息解读近期，A股市场中生物医药类企业的监管规则发生了调整，IPO行情呈现出持续走弱的态势。与此同时，港股市场却涌现出医药企业私有化退市的现象，并在年底显现出IPO回暖的趋势。此外，科创板的上市标准亦有所修改，提升了医药企业的上市门槛。...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2494064477?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-12-25 09:30","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2494064477","market":"sh","top_or_hot":-1,"title":"复旦复华涨5% 生物医药政策调整","media":"智选洞察","content":"<div>\n<p>12月25日，复旦复华（600624）股价大幅上涨，截至09点30分，复旦复华上涨5.14%，报7.78元/股，成交863万元，换手率0.16%，振幅0.14%。消息解读近期，A股市场中生物医药类企业的监管规则发生了调整，IPO行情呈现出持续走弱的态势。与此同时，港股市场却涌现出医药企业私有化退市的现象，并在年底显现出IPO回暖的趋势。此外，科创板的上市标准亦有所修改，提升了医药企业的上市门槛。...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241225093041984e0e81&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>复旦复华涨5% 生物医药政策调整</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n复旦复华涨5% 生物医药政策调整\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-25 09:30 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241225093041984e0e81&s=b><strong>智选洞察</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>12月25日，复旦复华（600624）股价大幅上涨，截至09点30分，复旦复华上涨5.14%，报7.78元/股，成交863万元，换手率0.16%，振幅0.14%。消息解读近期，A股市场中生物医药类企业的监管规则发生了调整，IPO行情呈现出持续走弱的态势。与此同时，港股市场却涌现出医药企业私有化退市的现象，并在年底显现出IPO回暖的趋势。此外，科创板的上市标准亦有所修改，提升了医药企业的上市门槛。...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241225093041984e0e81&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"600624","symbol_name":"复旦复华","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241225093041984e0e81&s=b","article_id":"2494064477","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241225093041984e0e81&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2494064477","pubTimestamp":1735090200,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"消息解读近期，A股市场中生物医药类企业的监管规则发生了调整，IPO行情呈现出持续走弱的态势。资金动向截止发稿，复旦复华获得主力净流入195万元，其中超大单流入235万元，大单流出39万元。主营业务及业绩复旦复华公司主营业务为软件开发、生物医药、科技园区产业。最新财报显示，今年三季报，复旦复华实现营业收入4.77亿元，同比减少7.86%，净利润为-3,220.86万元，同比减少565.95%，基本每股收益为-0.05元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"161726":"生物医药","399441":"生物医药","600624":"复旦复华","BK0188":"融资融券","BK0075":"新三板","BK0239":"医药制造","BK0122":"高校"},"translate_title":"Fudan Fuhua rose 5%, biomedical policy adjustments","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"161726":1,"399441":1,"600624":1},"content_text":"12月25日，复旦复华（600624）股价大幅上涨，截至09点30分，复旦复华上涨5.14%，报7.78元/股，成交863万元，换手率0.16%，振幅0.14%。消息解读近期，A股市场中生物医药类企业的监管规则发生了调整，IPO行情呈现出持续走弱的态势。与此同时，港股市场却涌现出医药企业私有化退市的现象，并在年底显现出IPO回暖的趋势。此外，科创板的上市标准亦有所修改，提升了医药企业的上市门槛。不仅如此，监管部门对于医药企业在推广销售费用方面的合理性与合规性给予了更高的关注。在深圳，科技创新种子基金已经实现了子基金首批投资项目的落地，重点投向生物医药和高性能材料两大领域。特别是，深圳市艾迪贝克生物医药有限公司作为种子基金的第一个投资项目，备受瞩目。这家初创公司专注于CRISPR基因编辑技术的新药开发，其CRISPR-Cas3的体内基因编辑疾病治疗技术在根治乙肝、艾滋病及疱疹病毒方面展现出巨大潜力。资金动向截止发稿，复旦复华获得主力净流入195万元，其中超大单流入235万元，大单流出39万元。数据显示，该股今日净流入较近5日净流入均值增加1790万元。主营业务及业绩复旦复华公司主营业务为软件开发、生物医药、科技园区产业。最新财报显示，今年三季报，复旦复华实现营业收入4.77亿元，同比减少7.86%，净利润为-3,220.86万元，同比减少565.95%，基本每股收益为-0.05元。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2494064477"}